A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subretinal OCU400 Gene Therapy for the Treatment of Retinitis Pigmentosa

Study Summary

This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 140 subjects. Study has completed enrollment of all 140 subjects.

Interventions

Study Locations

Facility	City	State	Country
Associated Retina Consultants	Phoenix	Arizona	United States
University of Southern Califormia	La Jolla	California	United States
University of Southern California, Roski Eye Insitute	Los Angeles	California	United States
Advanced Research, LLC.	Deerfield Beach	Florida	United States
Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine	Miami	Florida	United States
Erie Retina Research LLC	Erie	Pennsylvania	United States
Vanderbilt Eye Institute	Nashville	Tennessee	United States
Retina Consultants of Texas	Bellaire	Texas	United States
Retina Foundation of the Southwest	Dallas	Texas	United States
Baylor College of Medicine	Houston	Texas	United States
Valley Retina Institute	McAllen	Texas	United States
Gundersen Health System	La Crosse	Wisconsin	United States
Calgary Retina Consultants	Calgary	Alberta	Canada
University of Alberta	Edmonton	Alberta	Canada
The University of British Columbia	Vancouver	British Columbia	Canada
Sunnybrook Health Sciences Centre	Toronto	Ontario	Canada
Research Institute of the McGill University Health Centre	Montreal	Quebec	Canada

Official Trial Information

View on ClinicalTrials.gov